Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
To explore whether adding olanzapine to paclitaxel chemotherapy could improve chemotherapy
tolerance and improve patient quality of life and prolong treatment failure time (TTF) in
advanced gastric cancer after failure of first-line chemotherapy.
This is a multi-center prospective randomized controlled open clinical study. Patients will
formally be enrolled after they had been screened and signed informed consent. Baseline
examinations will be started after entry into the group. Those who meet the criteria for
inclusion and exclusion were dynamically randomized at 1: 1. The experimental group will
receive olanzapine and paclitaxel until treatment failure and the control group will receive
paclitaxel until treatment failure.